Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2009

01-10-2009 | Case Report

Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review

Authors: Jiun-I Lai, Wei-Shu Wang

Published in: International Journal of Clinical Pharmacy | Issue 5/2009

Login to get access

Abstract

Objective To report a case of immune mediated hemolysis occurring after oxaliplatin infusion in a patient with rectal cancer. Case summary We report a 69 year old male patient who presented with acute onset anemia after infusion of oxaliplatin as chemotherapy. A positive direct Coombs test and good response to steroids treatment underlined the diagnosis of immune related hemolytic anemia. The patient was switched to irinotecan-based chemotherapy regimen for further treatment. Discussion To our knowledge, there has been less than 10 cases of hemolysis occurring after oxaliplatin treatment in the medical literature. In all cases, immune mediated hemolysis has been proven with a positive coombs test. As oxaliplatin based chemotherapy regimen has become a standardized first line treatment for metastatic colorectal adenocarcinoma, this phenomenon warrants a higher level of physician awareness. Conclusions Oxaliplatin related hemolytic anemia is a rare reported phenomenon. Patient under oxaliplatin treatment presenting with sudden hemoglobin decrease should prompt further investigation of hemolysis.
Literature
2.
3.
go back to reference Cobo F, De Celis G, Pereira A, Latorre X, Pujadas J, Albiol S. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anticancer Drugs. 2007;18(8):973–6.PubMed Cobo F, De Celis G, Pereira A, Latorre X, Pujadas J, Albiol S. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anticancer Drugs. 2007;18(8):973–6.PubMed
5.
go back to reference Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology. 2004;67(2):179–82. doi:10.1159/000081006.CrossRefPubMed Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology. 2004;67(2):179–82. doi:10.​1159/​000081006.CrossRefPubMed
7.
go back to reference Hofheinz RD, Nguyen XD, Buchheidt D, Kerowgan M, Hehlmann R, Hochhaus A. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol. 2004;53(3):276–7. doi:10.1007/s00280-003-0731-8.CrossRefPubMed Hofheinz RD, Nguyen XD, Buchheidt D, Kerowgan M, Hehlmann R, Hochhaus A. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol. 2004;53(3):276–7. doi:10.​1007/​s00280-003-0731-8.CrossRefPubMed
9.
go back to reference Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5.CrossRefPubMedPubMedCentral Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5.CrossRefPubMedPubMedCentral
Metadata
Title
Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review
Authors
Jiun-I Lai
Wei-Shu Wang
Publication date
01-10-2009
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2009
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9313-0

Other articles of this Issue 5/2009

International Journal of Clinical Pharmacy 5/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.